Loading ...

Srinath Sanda, MD

Immune Tolerance Network

Director, Clinical and Translational Medicine, Clinical Trials Group

Assessment Group

Allergy & Asthma

Type 1 Diabetes

ssanda@immunetolerance.org

Work:

415-353-4414

Mobile:

Address:

Immune Tolerance Network

Committees:

,

Studies:

ITN043AD

-

Long-Term Effects of Sublingual Grass Therapy

ITN050AD

-

Peanut Oral Immunotherapy in Children

ITN028AI

-

Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes

ITN041AI

-

A Research Trial Of Aralast In New Onset Diabetes

ITN045AI

-

Inducing Remission in New Onset T1DM with Alefacept

ITN058AI

-

Preserving Beta Cell Function with Tocilizumab in New Onset Type 1 Diabetes

ITN065AI

-

TCZ in Pediatric New-onset T1D

ITN066AI

-

Type 1 Diabetes Extension Study

ITN078AI

-

Immunotherapy To Preserve Residual Insulin In New-Onset Type One Diabetes (IMPRINT)

ITN819AI

-

Type 1 Diabetes Immunotherapy Using Polyclonal Tregs

ITN072AD

-

GLA-AF plus antigen-specific immunotherapy in individuals with seasonal allergic rhinitis

Bio:

Admin Links

Shortcuts

ITN Documents

Links